Last Week in GER Research: Ascletis Pharma, China Tower, Pinduoduo, Beigene and CNFinance
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight our sensitivity analysis for Ascletis...
810 Views
BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term
The US-listed BeiGene (BGNE US) aims to list in Hong Kong by raising USD1 billion via issuing new shares. The company plans to use the majority of...
635 Views
BeiGene IPO Preview: Lucrative Lifesavers
BeiGene (BGNE US) is set to become the first overseas listed biotech firm to seek a secondary listing in Hong Kong, under the city’s newly revamped...
557 Views
Trade Risks Start to Impact, as China Biotech Ambitions Grow…
Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...
135 Views
Genomics as an Investment Theme
Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...
314 Views